BNOS 2022 | Novel perspectives in glioblastoma immunotherapy

Hemanth Vupputuri, MBBS, The Walton Centre NHS Foundation Trust, Liverpool, UK, comments on the need for more immunotherapies in the field of glioblastoma. Whilst patients with other cancers such as breast cancer have benefited from immunotherapy, patients with primary brain tumors including glioblastoma still have average survival rates of under a year. The development of monoclonal antibodies will hence optimize outcomes for patients with glioblastoma. This interview took place at the British Neuro-Oncology Society (BNOS) Annual Meeting 2022.